NCT05865990 - HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions

Metastatic Breast CancerAdvanced Non-Small Cell Squamous Lung CancerSolid Tumor, Adult

Interventions

DRUG

Patritumab deruxtecan

HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.

Trial Locations (8)

Unknown

Salzburg Cancer research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg

Medical University of Vienna, Vienna

Hospital Universitari Dexeus, Barcelona

Hospital Universitari Vall D'Hebron, Barcelona

Hospital Beata María Ana, Madrid

Hospital Quirónsalud Sagrado Corazón, Seville

Hospital Universitario Virgen del Rocío, Seville

Hospital Arnau de Vilanova de Valencia, Valencia